The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•28 March 2026•

1 min read

Corcept Therapeutics Shares Surge 9% Following FDA Approval for Cancer Drug Lifyorli

Fortified uniQure building, fences, caution tape, security cameras. FDA buildings, US flags, justice symbols. Charts on tablets and papers.

Key Facts

1Corcept Therapeutics received FDA approval for its cancer drug, Lifyorli.

2The company's stock rose nearly 9% during the week following this regulatory milestone.

Version History

1 additional source confirmed this story

Corcept Therapeutics (CORT) witnessed a significant rally this week, with its share price climbing approximately 9%. The surge follows the U.S. Food and Drug Administration (FDA) granting approval for the company's oncology treatment, Lifyorli. This regulatory milestone marks a critical breakthrough for the biotech firm's pipeline development. In response to the news, financial analysts have upgraded their recommendations for the stock, citing improved growth prospects. The approval is expected to strengthen Corcept's market position within the competitive oncology sector. Investors reacted positively to the dual impact of regulatory success and favorable analyst sentiment.